Compare ACEL & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | FLGT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.7M | 867.4M |
| IPO Year | 2017 | 2016 |
| Metric | ACEL | FLGT |
|---|---|---|
| Price | $11.72 | $14.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $14.67 | ★ $28.33 |
| AVG Volume (30 Days) | 406.6K | ★ 486.9K |
| Earning Date | 06-04-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $5.86 | $10.66 |
| Revenue Next Year | $3.05 | $12.17 |
| P/E Ratio | $20.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.02 | $13.46 |
| 52 Week High | $13.31 | $31.04 |
| Indicator | ACEL | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 20.89 |
| Support Level | $10.95 | N/A |
| Resistance Level | $12.92 | $19.96 |
| Average True Range (ATR) | 0.42 | 0.99 |
| MACD | 0.12 | -0.83 |
| Stochastic Oscillator | 38.91 | 9.87 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.